An intraocular shunt can be placed into the eye in an ab externo approach. A clinician may determine an entry area below a corneal limbus of an eye and a target outflow region. Thereafter, the clinician can insert a hollow shaft into the eye at the entry area toward an anterior chamber of the eye, the shaft carrying an intraocular shunt therein. The clinician can position an inflow end of the shunt within the anterior chamber of the eye and, while maintaining the shunt inflow end in the anterior chamber, can remove the shaft from the eye to release the shunt. Finally, the clinician can repositioning an outflow end of the shunt within the target outflow region and verify placement of the outflow end of the shunt within the target outflow region.

An improved method and device are provided for treating wounds. The device generally comprises a wound chamber and/or deployment system. The provided assembly substantially improves wound treatment.

Disclosed herein are drug delivery devices and methods for the treatment of ocular disorders requiring targeted and controlled administration of a drug to an interior portion of the eye for reduction or prevention of symptoms of the disorder. The devices are capable of controlled release of one or more drugs and may also include structures which allows for treatment of increased intraocular pressure by permitting aqueous humor to flow out of the anterior chamber of the eye through the device.

Delivery devices, systems and methods are provided for inserting an implant into an eye. The delivery or inserter devices or systems can be used to dispose or implant an ocular stent or implant, such as a shunt, in communication with a suprachoroidal space of the eye. The implant can drain fluid from an anterior chamber of the eye to a physiologic outflow path of the eye, such as, the suprachoroidal space or other portion of the uveoscleral outflow path. The delivery or inserter devices or systems can be used in conjunction with other ocular surgery, for example, but not limited to, cataract surgery through a preformed corneal incision, or independently with the inserter configured to make a corneal incision. The implant can be preloaded with or within the inserter to advantageously provide a sterile, easy-to-use package for use by an operator.

A solid matrix sustained release ophthalmic formulation for topical delivery of a solid ophthalmic drug to the eye, medical devices, drug cores, drug inserts and drug delivery systems comprising the formulation, methods of manufacturing the formulation, medical devices and their methods thereof for delivering the ophthalmic drug for a treatment period provided herein. The formulation disclosed herein is an admixture of an ophthalmic drug, and a combination of a hydrophobic polymer, a hydrophilic polymer and a surfactant, wherein the drug is eluted daily over an extended period of time at therapeutic dose of drug.

A light adjustable lens illumination system comprises an illumination source, for generating a light beam; a light delivery system, for projecting the light beam onto a Light Adjustable Lens (LAL), implanted into an eye, wherein a fraction of the light beam propagates past the LAL to a retina of the eye; and a protective beam-shaper, for shaping the light beam to have an intensity pattern with a relative central intensity reduction that varies along an axis; wherein the relative central intensity reduction at the retina is greater than the relative central intensity reduction at a LAL plane.

A fluid dispensing device includes a cartridge comprising a housing and a head coupled to the housing. The housing forms a first chamber configured to accommodate a fluid; and the head includes a nozzle; and an elastomeric wall that is spaced from the nozzle to form a holding chamber. The holding chamber is in fluid communication with the first chamber and configured to accommodate a portion of the fluid; and the nozzle forms one or more openings to eject the portion of the fluid from the holding chamber. The one or more openings form an oblong shape such that a length of the oblong shape is greater than a width of the oblong shape. The one or more openings can include two parallel slots that together form the oblong shape.

The eye drop container includes a container body having an inner plug and an opening part in which the inner plug is mounted. The inner plug is mounted in the opening part of the container body, constitutes a nozzle part, and has a liquid-contacting part which is constituted of a layer including a cyclic olefin copolymer, a cushioning part which is provided in an outer circumferential part in contact with the opening part, a flange part which comes into contact with a tip surface of the opening part, and a leg part which comes into contact with an inner surface of the opening part. The cushioning part is provided on at least an outer circumferential surface of the leg part.

This invention relates to novel implant drug delivery systems for long-acting delivery of mometasone furoate. These compositions are useful for the treatment or prevention of inflammatory conditions of the eye.

The present disclosure describes a method for treating or preventing an inflammatory ocular surface disease or disorder, such as ocular graft-versus-host disease, dry eye, meibomian gland disease, thyroid eye disease, blepharitis, Sjogren's syndrome, peripheral ulcerative keratitis, or Stevens-Johnson syndrome, in a human subject in need thereof, the method comprising (a) administering a topical progesterone composition to the forehead of the subject; (b) administering punctal plugs to the subject; and (c) administering a opical corticosteroid composition, such as loteprednol etabonate ointment, to the eye of the subject. Such administration methods may also be useful in improving corneal health before cataract surgery and/or promoting healing of the cornea after cataract surgery.